Flow Cytometry – Products

Spatial biology requires highly validated reagents to accurately resolve proteins in the tissue microenvironment. Although immunofluorescence techniques are some of the most commonly used research tools, there are no universally accepted guidelines for antibody validation.

Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. has announced that it has entered into a strategic partnership with Bio-Rad Laboratories, Inc.

The new service is a world first in 3D imaging, allowing the measurement and visualization of tumor growth in animal models across preclinical research, oncology and drug development.

Traditional methods are often low throughput, time-consuming and lack linearity. However, advanced flow cytometry has emerged as a more efficient alternative for biologics development.

With the CellCelector Flex single cell and colony picking platform, you can now effectively assess and verify your clones before deciding which ones to choose. In less than one week, you will obtain monoclonal, viable, and productive colonies from your pool of single cells. Instead of relying on large quantities of plates to produce a winner you can now use actual data to reliably predict the future of your clones. This saves consumable and media costs, incubator space, and most of all valuable time by avoiding missteps, a second cloning round, and unnecessary procedures

The cell therapy manufacturing process requires the guidance of chemical manufacturing and controls for analytical method development focusing on the critical quality attributes (CQAs).

Flow cytometry has enabled the discovery of varied and nuanced cell types in terms of phenotypic markers and biological functions, but the visible spectrum places limitations on the number of extrinsic parameters that can be assessed.

Beckman Coulter Life Sciences introduces an automated solution for the grueling and time-consuming process of manual gating flow cytometry data, with no programming skills required.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

AMSBIO offer an extensive range of highly characterized, high purity exosomes for use as control standards in applications including marker assessment, immunocapture performance evaluation, exosome quantification, OMICS analysis, flow cytometry and electron microscopy.